Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bpl bioproducts laboratory gmbh (4612007) - immunglobulin g vom menschen - infusionslösung - teil 1 - infusionslösung; immunglobulin g vom menschen (24101) 98 prozentgehalt masse in masse

ABD - İngilizce - NLM (National Library of Medicine)

delilah cosmetics - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) -

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

nestmann pharma gmbh (3061841) - selenium (pot.-angaben); avena sativa (pot.-angaben); camphora (pot.-angaben); semecarpus anacardium (pot.-angaben); panax ginseng (pot.-angaben); zincum metallicum (pot.-angaben); coffeinum (pot.-angaben); cola (pot.-angaben) - mischung - teil 1 - mischung; selenium (pot.-angaben) (03069) 2 gramm; avena sativa (pot.-angaben) (01621) 0,5 gramm; camphora (pot.-angaben) (01800) 0,2 gramm; semecarpus anacardium (pot.-angaben) (02153) 1 gramm; panax ginseng (pot.-angaben) (06830) 2 gramm; zincum metallicum (pot.-angaben) (03393) 1 gramm; coffeinum (pot.-angaben) (03844) 0,8 gramm; cola (pot.-angaben) (07849) 1 gramm

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

bpl bioproducts laboratory gmbh - human normal immunoglobulin - solution for infusion - 100 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.344 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 113.376 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

ABD - İngilizce - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - divalproex sodium is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. the efficacy of divalproex sodium delayed-release tablets was established in 3-week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania [see clinical studies (14.1)] . the safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual pat

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

athlone pharmaceuticals limited - trimethoprim - tablet - trimethoprim and derivatives; trimethoprim

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

athlone pharmaceuticals limited - trimethoprim - tablet - trimethoprim and derivatives; trimethoprim